Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

Publisher： Karger

E-ISSN： 1423-0356|92|2|98-106

ISSN： 0025-7931

Source： Respiration, Vol.92, Iss.2, 2016-08, pp. : 98-106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report

By  

Respiration, Vol. 91, Iss. 4, 2016-04 ,pp. : 327-332

Karger

Access to resources Recommend Favorite

Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side

By  

Respiration, Vol. 86, Iss. 6, 2013-12 ,pp. : 441-452

Karger

Access to resources Recommend Favorite

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

By  

Respiration, Vol. 93, Iss. 5, 2017-03 ,pp. : 363-378

Karger

Access to resources Recommend Favorite

Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail

By  

RESPIROLOGY (ELECTRONIC), Vol. 23, Iss. 3, 2018-03 ,pp. : 244-245

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases

By  

Respiration, Vol. 88, Iss. 3, 2014-08 ,pp. : 199-207

Karger

Access to resources Recommend Favorite